Stelexis Therapeutics is a groundbreaking brand dedicated to revolutionizing cancer treatment through the discovery of new targets that target the origin of tumors. They recognize that pre-cancer and cancer stem cells play a crucial role in the progression and relapse of cancer, yet they are often resistant to conventional treatments. With their proprietary platform called TumorOrigin™, Stelexis has overcome the challenges of studying and isolating these elusive cells for drug discovery.

Their innovative approach involves utilizing large banks of patient-derived samples to isolate, expand, and maintain cancerous stem cells. By doing so, they are able to uncover novel, druggable targets on these cells, providing unprecedented opportunities for effective therapeutic interventions. Stelexis is currently advancing two lead candidates, STLX1018 and STLX2012, which target cancerous stem cells in acute myeloid leukemia (AML) and solid tumors.

At Stelexis, a team of experienced professionals is dedicated to improving the lives of cancer patients. Their commitment to discovering and developing novel oncology therapeutic approaches drives their mission forward. With their headquarters in New York, they are at the forefront of cutting-edge cancer research and strive to make a significant impact in the field